Refractory hematopoietic cell transplantation autologous transplantation. Medical search. Frequent questions

Eileen P. Smith, M.D., has spent nearly three decades at City of Hope, beginning in 1988 as a fellow in medical oncology and bone marrow transplantation. (cityofhope.org)
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP). (wizaxe-prod.com)
Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation. (wizaxe-prod.com)
Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. (cdc.gov)

And investigators are examining the safety and efficacy of autologous hematopoietic stem cell transplantation to treat refractory and severe myasthenia gravis. (abingtonneurology.com)
Stem Cells in MS Show Promise The results of this trial suggest that RCTs to assess safety and efficacy of autologous hematopoietic SCT in multiple sclerosis are warranted, says Dr Barclay. (medscape.com)

Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. (nih.gov)
12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. (nih.gov)
Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. (nih.gov)
Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge. (nih.gov)
Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). (who.int)

Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
Peripheral blood progenitor cells and/or bone marrow were infused on day 0. (duke.edu)
1 Treatment with progenitor cells (i.e., stem cells) offers potential benefits beyond those of standard medical care, including the potential for repair and/or regeneration of damaged myocardium. (southcarolinablues.com)

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. (ashpublications.org)

High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)

The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
Scholars@Duke publication: Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. (duke.edu)
High-dose CBV (cyclophosphamide, carmustine, and etoposide) in combination with autologous HCT achieves survival rates of approximately 50% at 5 years in recurrent or refractory Hodgkin's disease (HD). (duke.edu)
Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)

Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
B-cell maturation antigen-(BCMA) targeted CAR T-cells are approved for relapsed and/or refractory multiple myeloma . (cancercenter.com)
A CAR T-cell study out of Massachusetts General Hospital , reported in Blood Advances in July, looked at 100 patients who received some form of CAR T-cell therapy for lymphoma, myeloma or B-cell acute lymphoblastic leukemia. (cancercenter.com)
Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (medivizor.com)
Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. (medivizor.com)
We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival. (elsevierpure.com)
Methods: Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. (elsevierpure.com)
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (drugs.com)
1 As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells. (drugs.com)
CAR T cell therapies have shown transformational potential for the treatment of hematologic malignancies, and we, with our partners at bluebird bio, are proud to bring the first CAR T cell therapy to appropriate triple-class exposed patients with relapsed or refractory multiple myeloma, offering the chance for durable response," said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb. (drugs.com)
4-9 Patients with relapsed or refractory multiple myeloma that have been exposed to all three major drug classes (triple-class exposed), including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, tend to demonstrate poor clinical outcomes with very low response rates (20% to 30%), short duration of response (2 to 4 months) and poor survival. (drugs.com)
In the KarMMa study, ide-celelicited rapid responses in the majority of patients, and these deep and durable responses were observed in patients with triple-class exposed and refractory multiple myeloma," said Nikhil C. Munshi, M.D., Associate Director, The Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Boston, Massachusetts. (drugs.com)
As a treating physician, I often work with patients with relapsed or refractory multiple myeloma who are in critical need of new therapies. (drugs.com)
Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (msdmanuals.com)

or relapsed or refractory disease after ≥2 lines of systemic therapy. (empr.com)

A randomized phase III trial of consolidation with autologous hematopoietic cell transplantation followed by maintenance rituximab vs. maintenance rituximab alone for patients with mantle cell lymphoma in minimal residual disease-negative first complete remission. (slu.edu)
Conclusion Daratumumab was safe and effective in inducing remission in two patients with severe treatment-refractory AAV, warranting prospective clinical trials to establish safety and efficacy. (bmj.com)
CD patients maintained high remission rates for 3-24 months after transplantation. (biomedcentral.com)
Patients and Methods We performed a multicenter retrospective study of DLBCL patients who underwent auto-HCT (n = 160), who experienced complete remission after transplantation, and who then underwent surveillance imaging. (northwestern.edu)
However, in these patients, conventional-dose chemotherapy regimens induce low remission rates, resulting in long-term remissions in approximately 40-50% of relapsed patients and in up to 25-30% of those with primary refractory disease. (wjon.org)
Introduction: Patients (pts) with primary refractory or relapsed high-grade lymphoma (HGL) including Burkitt lymphoma (BL) and high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 (double-hit lymphoma, DHL) have a dismal prognosis with patients almost never achieving a meaningful remission to second line therapy. (bvsalud.org)
In the initial phase I trial (n=26) one patient with multiply refractory BL had a partial remission sustained for over one year and then consolidated by surgical resection. (bvsalud.org)

We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients. (frontiersin.org)
She is currently running a clinical trial examining the effectiveness of administering a double or "tandem" dose of a patient's own healthy stem cells within a relatively short period of time. (cityofhope.org)
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (cityofhope.org)
HCT in EAE mice leads to an enhancement of this myeloid state, as well as clinical improvement, reduction of demyelinated lesions, suppression of cytotoxic T cells, and amelioration of reactive astrogliosis reflected in reduced expression of EAE-associated gene signatures in oligodendrocytes and astrocytes. (stanford.edu)
Here, we describe the pre-clinical in vitro and in vivo study of irradiated haNK cells engineered to express a second-generation chimeric antigen receptor (CAR) targeting programmed death-ligand 1 (PD-L1). (elifesciences.org)
Tumor stem cell-targeted immunotherapy for metastatic melanoma -a randomized phase 3 clinical trial. (ca.gov)
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. (unm.edu)
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
Clinical improvement was paralleled by a strong reduction in serum ANCA levels as well as total IgG, indicating depletion of plasma cells. (bmj.com)
Chronic inflammatory demyelinating polyneuropathy (CIDP) has a variable clinical course with 15% remaining refractory to treatment. (bmj.com)
In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
Overall, this evidence has suggested that progenitor cell treatment may be a promising intervention, but robust data on clinical outcomes are lacking. (southcarolinablues.com)
Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
However, melphalan efficacy is variable in the clinical population, especially in relapsed and refractory MM, and is also implicated in various toxicities, including severe mucositis and myelosuppression. (snmjournals.org)
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. (wizaxe-prod.com)
Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. (catalent.com)
Catalent Biologics' Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. (catalent.com)
Breyanzi is shipped directly to the cell lab or clinical pharmacy associated with the infusion center in the vapor phase of a liquid nitrogen shipper. (empr.com)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)

High-dose chemotherapy (using a different chemotherapeutic agent) and autologous stem cell transplantation (SCT) is considered the treatment of choice in a subset of patients. (wjon.org)
High-dose melphalan followed by autologous peripheral blood stem cell transplantation may also be used. (msdmanuals.com)

Mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) have been shown to counter rheumatoid arthritis, autoimmune hepatitis, and systemic sclerosis [ 8 ]. (biomedcentral.com)

However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. (bvsalud.org)
CD19-directed genetically modified autologous T cell immunotherapy. (empr.com)

Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems. (catalent.com)

Clinically, grade 3B follicular lymphoma is treated like diffuse large B-cell lymphoma . (medscape.com)
Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
A recently published study showed that when patients have an early first relapse of their diffuse large B-cell lymphoma (DLBCL) patients have better outcomes," says Leslie Popplewell , MD, Medical Director of Hematology and Blood and Marrow Transplant at City of Hope ® Cancer Center Atlanta . (cancercenter.com)
CAR T-cell therapy has really begun to displace autologous stem cell transplants as the preferred treatment for diffuse, large B-cell lymphoma [DLBCL] in early first relapse," Dr. Popplewell says. (cancercenter.com)
Background For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), autologous hematopoietic cell transplantation (auto-HCT) is commonly used. (northwestern.edu)

The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time. (stembook.org)
A study to evaluate stem cell collection times for patients seen at the Outpatient Bone Marrow Transplant Center at SSM Health Saint Louis University Hospital. (slu.edu)
The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)
Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (msdmanuals.com)
Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (msdmanuals.com)

We report a woman with severe refractory CIDP and coexisting chronic lymphocytic leukaemia (CLL) who improved dramatically after chemoimmunotherapy appropriate for the CLL, including rituximab. (bmj.com)
Hematopoietic stem cell transplantation in a severe refractory Crohn's disease patient with intestinal stoma: a case report. (wizaxe-prod.com)

Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (msdmanuals.com)

Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)

Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia. (stembook.org)
Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia. (stembook.org)
Indication The target indication is relapsed/refractory secondary acute myeloid leukemia (sAML), or int-2 or high-risk myelofibrosis (MF). (ca.gov)
Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
CAR T-cell therapy that targets the CD19 antigen is now approved for relapsed and/or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia. (cancercenter.com)
Progenitor cell therapy is being investigated for the treatment of damaged myocardium resulting from acute or chronic cardiac ischemia and for refractory angina. (southcarolinablues.com)
For individuals who have acute cardiac ischemia who receive progenitor cell therapy, the evidence includes 2 randomized controlled trials (RCTs) with 200 patients, numerous small RCTs, and meta-analyses of these RCTs. (southcarolinablues.com)
Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation. (medivizor.com)
In a nutshell This study evaluated the tolerability and effectiveness of combined therapy using venetoclax (Venclexta) and gilteritinib (Xospata) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with the FLT3 (FMS-related tyrosine kinase 3) mutation. (medivizor.com)
Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analysis. (gilead.com)

Nevertheless, ex vivo activation with cytokines can restore cytolytic activity of NK cells against GB, indicating that NK cells have potential for adoptive immunotherapy of GB if potent cytotoxicity can be maintained in vivo . (frontiersin.org)
Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. (frontiersin.org)
Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. (elifesciences.org)
T cell-based immunotherapy, such as immune checkpoint blockade or adoptive T cell transfer, is limited by the ability of T cells to detect major histocompatibility complex (MHC)-presented antigen by tumor cells. (elifesciences.org)
Natural killer (NK) cell-based immunotherapy may overcome genetic mechanisms of resistance to T cell-based immunotherapy through antigen- and MHC-independent recognition of malignant cells. (elifesciences.org)
Thus, addressing the presence of immunosuppressive myeloid cell populations in the periphery and tumor microenvironment of patients with cancer is likely to be required for effective NK cell-based immunotherapy. (elifesciences.org)
Therapeutic Candidate or Device Tumor stem cell-targeted immunotherapy. (ca.gov)
Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
Abecma will be manufactured for each individual patient using the patient's own T cells at Bristol Myers Squibb's state-of-the-art cellular immunotherapy manufacturing facility in Summit, New Jersey. (drugs.com)

Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma. (medivizor.com)
In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. (wjon.org)

Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. (cdc.gov)
On May 27, 2022 , tisagenlecleucel, a CD19 chimeric antigen receptor (CAR) T-cell therapy, was granted accelerated approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. (ascopost.com)
Approval was based on the multicenter ELARA trial (ClinicalTrials.gov identifier NCT03568461) in patients who were refractory or relapsed within 6 months after completion of at least two lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or who relapsed after autologous hematopoietic stem cell transplantation. (ascopost.com)
Tisagenlecleucel was granted accelerated approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. (ascopost.com)
A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer's disease. (stanford.edu)
Autologous hematopoietic cell transplantation (HCT) is under investigation as a promising therapy for treatment-refractory MS. Here we identify a reactive myeloid state in chronic experimental autoimmune encephalitis (EAE) mice and MS patients that is surprisingly associated with neuroprotection and immune suppression. (stanford.edu)
Therapeutic Candidate or Device Rebecsinib is a novel small molecule inhibitor of ADAR1 splicing that selectively eradicates therapy-resistant cancer stem cells in blood cancers. (ca.gov)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development. (hindawi.com)
Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. (bvsalud.org)
What Happens if CAR T-Cell Therapy Fails? (cancercenter.com)
And, if CAR T-cell therapy fails, standardized treatment protocols have yet to be determined to stop the cancer from growing, though some treatments have shown limited success. (cancercenter.com)
Emily Whitehead was 6 years old and near death at the Children's Hospital of Philadelphia when she became the first pediatric patient to receive yet-to-be approved chimeric antigen receptor (CAR) T-cell therapy to treat her leukemia. (cancercenter.com)
Emily is one of many success stories of CAR T-cell therapy in the treatment of blood cancers. (cancercenter.com)
CAR T-cell therapy is predominantly used for patients after two or more other therapies have failed. (cancercenter.com)
We are moving CAR T-cell therapy up sooner in treatment. (cancercenter.com)
What is CAR T-cell therapy? (cancercenter.com)
What is the CAR T-cell therapy success rate? (cancercenter.com)
We explored whether stem cell therapy was effective for animal models and patients with Crohn's disease (CD). (biomedcentral.com)
Stem cell transplantation is a valuable supplementary therapy for CD. (biomedcentral.com)
Several studies have evaluated the safety and effectiveness of CD stem cell therapy, but the results remain controversial. (biomedcentral.com)
Progenitor cell therapy describes the use of multipotent cells of various cell lineages (autologous or allogeneic) for tissue repair and/or regeneration. (southcarolinablues.com)
For individuals who have chronic cardiac ischemia who receive progenitor cell therapy, the evidence includes a nonrandomized comparative trial and systematic reviews of smaller RCTs. (southcarolinablues.com)
For individuals who have refractory angina who receive progenitor cell therapy, the evidence includes phase 2 trials and a phase 3 pivotal trial. (southcarolinablues.com)
Additional larger trials are needed to determine whether progenitor cell therapy improves health outcomes in patients with refractory angina. (southcarolinablues.com)
Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
Future work will explore additional MM cell lines with heterogeneous LAT1 expression and response to melphalan therapy. (snmjournals.org)
Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. (wizaxe-prod.com)
A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. (wizaxe-prod.com)
Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma. (medivizor.com)
Even though cHL is highly curable, around 25% of the patients with cHL have a refractory or relapsed disease after the first-line therapy [ 5 ]. (wjon.org)
Patients must have had at least one prior line of therapy or are refusing standard of care and must be more than 3 months after a prior stem cell transplant. (bvsalud.org)
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus ® (brexucabtagene autoleucel). (gilead.com)
ZUMA-3 is an ongoing international multicenter (US, Canada, Europe), single arm, open label, registrational Phase 1/2 study of Tecartus in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. (gilead.com)
Relapsed/refractory after 1 line of therapy: give a single dose of 90-110×10 6 CAR-positive viable T cells (consisting of 1:1 CD8 and CD4 components), with each component supplied separately. (empr.com)
Abecma is a personalized immune cell therapy approved as a one-time infusion with a recommended dose range of 300 to 460 x 10 6 CAR-positive T cells. (drugs.com)
As our second FDA-approved CAR T cell therapy, Abecma underscores our commitment to deliver on the promise of cell therapies for patients who are battling aggressive and advanced blood cancers with limited effective treatment options. (drugs.com)
Now, with the approval of ide-celas the first anti-BCMA CAR T cell therapy, we are excited to finally be able to offer patients a new, effective personalized treatment option that is delivered through a single infusion. (drugs.com)

A respected specialist in the field, Dr. Smith is a professor and chair of City of Hope's Department of Hematology & Hematopoietic Cell Transplantation . (cityofhope.org)

Younger Matched Unrelated Donors Confer Decreased Relapse Compared to Older Sibling Donors in Older B-cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. (stembook.org)
Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
however, patients who experience early relapse, or who are refractory to initial immunochemotherapy have a poor prognosis ( 3 ). (frontiersin.org)

Following lymphodepleting chemotherapy, tisagenlecleucel was given via a single intravenous infusion with a target dose of 0.6 to 6.0 × 10 8 chimeric antigen receptor (CAR)-positive viable T cells. (ascopost.com)
Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. (elifesciences.org)

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. (stembook.org)
Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. (lookformedical.com)
T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)

Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)
Figure 1 shows the trend in the annual number of allogeneic and autologous HCTs in adults with AML reported in the Japanese transplantation registry. (apbmt.org)
In adults, B-cell precursor ALL is the most common form, accounting for 75% of cases. (gilead.com)

One emerging treatment option for several antibody-mediated autoimmune diseases is the anti-CD38 antibody daratumumab, which depletes autoantibody-secreting plasma cells. (bmj.com)
In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmune diseases. (biomedcentral.com)

Therapeutic Mechanism Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival. (ca.gov)
Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
Blood is removed from the patient, it is spun in an apheresis machine to extract the T-cells. (cancercenter.com)
The lab re-engineers the T-cells by inserting genetic information that directs the T-cells to make receptors for the specific type of cancer cells in the patient. (cancercenter.com)
The patient typically undergoes a lymphocyte-depleting regimen of chemotherapy prior to the infusion of the CAR T-cells. (cancercenter.com)

Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necessitating the stratification of responding patients to minimize toxicities and improve quality of life. (snmjournals.org)

NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. (frontiersin.org)

Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with ex vivo activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. (frontiersin.org)
Treatment with Tofacitinib in refractory psoriatic arthritis. (unican.es)
Product labeling provides instructions on lymphodepleting treatment, premedication, and management of adverse reactions including cytokine-release syndrome and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome. (ascopost.com)
Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. (elifesciences.org)
Indication AiPSC-RPE cell product will be indicated for the treatment of maculopathies related to RPE atrophy. (ca.gov)
Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)
Objective Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening condition without evidence-based treatment options. (bmj.com)
The case suggests that CIDP refractory to conventional treatment may have associated pathology, in this case haematological malignancy, and that treating the malignancy can effectively treat the CIDP. (bmj.com)
In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. (biomedcentral.com)
Results of the nonrandomized trial are encouraging, because this is the first controlled trial that has reported a significant mortality benefit for progenitor cell treatment. (southcarolinablues.com)
A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: Progress Made and Future Directions. (wizaxe-prod.com)
Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. (wizaxe-prod.com)
Rituximab Effective, Durable in Refractory Myasthenia Gravis Dr Laurie Barclay discusses results from a small study and what they may mean for incorporating rituximab in the treatment of myasthenia gravis. (medscape.com)

While GB tumors are frequently infiltrated by natural killer (NK) cells, these are actively suppressed by the GB cells and the GB tumor microenvironment. (frontiersin.org)

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. (wizaxe-prod.com)
Autologous hematopoietic stem cells for refractory Crohn's disease. (wizaxe-prod.com)
Resetting of the Mucosal T Cell Repertoire after Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease. (wizaxe-prod.com)
Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. (wizaxe-prod.com)

Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. (stembook.org)
Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
Among the changes to CTCL classification were the addition of primary cutaneous acral CD8 + T-cell lymphoma as a new provisional entity. (medscape.com)

In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)

The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
However, from the beginning of puberty after thymus degeneration, human cytomegalovirus (HCMV) persists due to the chronic activation of cytomegalovirus in humans causing repeated activation of T cells, which is considered the driving factor of human immune aging [ 9 ]. (hindawi.com)
T-cells are white blood cells that the immune system produces to help destroy foreign cells. (cancercenter.com)
Immune checkpoint inhibitors such as the anti-programmed death 1 (PD-1) receptor antibodies have recently been approved to treat relapsed and refractory cHL and have significantly improved the outcome of patients with rrcHL. (wjon.org)
The approved immune checkpoint inhibitors for relapsed and refractory cHL are nivolumab and pembrolizumab. (wjon.org)

Anatomy22

Organisms14

Diseases45

Chemicals and Drugs40

Analytical, Diagnostic and Therapeutic Techniques and Equipment95

Psychiatry and Psychology1

Phenomena and Processes28

Anthropology, Education, Sociology and Social Phenomena3

Humanities1

Information Science4

Named Groups6

Health Care33

Geographicals1

MARROW TRANSPLANTATION11

Safety and efficacy of autologous hematopoietic2

HSCT9

Progenitor cells3

Salvage Therapy1

Chemotherapy and autologous1

Hodgkin's7

Myeloma19

Relapsed or refractory disease1

Remission7

Clinical26

High-dose2

Mesenchymal stem1

Genetically modified autologous2

20191

Diffuse5

Bone5

Severe refractory2

Efficacy1

DLBCL2

Acute11

Immunotherapy10

Classical Hodgkin3

Therapy38

Department of Hematology1

Relapse3

Chimeric antigen receptor2

Malignancies7

Adults3

Autoimmune diseases2

Patient5

Melphalan1

Dendritic cells1

Treatment13

Tumors1

Crohn's4

Primary3

Survival1

Immune5